PPD DEVELOPMENT LP

BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.

NIAID CLINICAL SITE MONITORING (NCSM)

COMPREHENSIVE AND RAPID RESPONSE FOR NIAID RESEARCH PROGRAMS HIV AND OTHER INFECTIOUS DISEASES CLINICAL RESEARCH SUPPORT SERVICES (CRSS)

RESEARCH AND DEVELOPMENT FOR CLINICAL STUDIES IN THE BLUEPRINT MEDTECH. CLINICAL STUDY PROTOCOL DEVELOPMENT. TASK ORDER 02. 06/17/2024 - 06/16/2029. BASE AND EXERCISE 2 UNITS OF OPTION QUANTITY 1.

ASSESSING CLINICAL SITE READINESS: A FRAMEWORK TO SUPPORT ENROLLMENT OF UNDER-REPRESENTED MINORITIES IN MEDICAL DEVICE CLINICAL TRIALS (FY23C1FWP6)

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) CLINICAL SITE MONITORING CENTER (CSMC)

REGULATORY CONSULTING ASSISTANCE FOR MEDICAL DEVICE DEVELOPER. RESEARCH AND DEVELOPMENT FOR CLINICAL STUDIES IN THE BLUEPRINT MEDTECH. TASK ORDER 02. 09/15/2023 - 09/14/2024.

REGULATORY MANAGEMENT CENTER (RMC)

FIRST IN HUMAN RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED SINGLE ASCENDING DOSE (SAD) PHASE I STUDY

FDABAA-24-00123, REF # FY24C1EP6, CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME PATIENT-REPORTED OUTCOME (PRO) BURDEN MEASURE

BAA-FY24C3CP5-UNDERSTANDING HETEROGENEITY IN PREFERENCES FOR CLINICAL TRIAL PARTICIPATION IN DIVERSE PATIENT POPULATIONS.

TO PROVIDE MONITORING SERVICES FOR ONE (1) PHASE III CLINICAL TRIAL, A5300B/PHOENIX